Jubilant Life Sciences has received the final approval from the US health regulator for Darifenacin Extended-Release Tablets, used for the treatment of urinary incontinence.
The company has “received Abbreviated New Drug Application (ANDA) final approval for Darifenacin Extended-Release Tablets, 7.5 mg and 15 mg, the generic version of Enablex of Allergan Plc, which is used for the treatment of urinary incontinence,” Jubilant Life Sciences said in a BSE filing.
Jubilant said it has received six approvals from the USFDA during the year.
As on June 30, 2016, Jubilant Life Sciences had 70 ANDAs for oral solids filed in the US, of which 44 have been approved.
Shares of Jubilant Life Sciences were trading 1.56 per cent lower at Rs 641 on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.